Feb 5 2011
Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
Israel's Magen David Adom, or Red Shield of David, is the international equivalent of the Red Cross or Red Crescent. Magen David Adom are responsible for and overlook all of the national blood banks that provide blood to Israeli hospitals and other Medical Clinics in Israel.
Discussions are to focus on implementing Medisafe 1 Technology's patented pre-matching safety locking device on blood bags and vials. Using the technology, a barcode reader would need to electronically confirm that a particular patient was being administered the appropriate and correct blood type prior to the release of the blood from the vial .
Medisafe 1 have had similar discussions with blood banks in the United States.
"We are hopeful that the future implementation of the technology in Israel Blood Banks will lead to its implementation in other countries," said Jacob Elhadad, CEO of Medisafe 1 Technologies.
Medisafe 1 Technologies has already developed its locking device technology for syringes in hospitals. It is estimated that the application of the technology for infusion bags will be ready for demonstration within three months' time.
SOURCE Medisafe
Red light therapy shown to significantly reduce blood sugar spikes, study finds